Your browser doesn't support javascript.
loading
Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation.
Yin, Liang; Liu, Kai-Cai; Lv, Wei-Fu; Xu, Shao-Bao; Lu, Dong; Zhou, Chun-Ze; Cheng, De-Lei; Gao, Zong-Gen; Shi, Chang-Sheng; Su, Ming-Xue.
Afiliação
  • Yin L; Department of Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230022, People's Republic of China.
  • Liu KC; Infection Hospital, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230000, People's Republic of China.
  • Lv WF; Department of Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230022, People's Republic of China.
  • Xu SB; Infection Hospital, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230000, People's Republic of China.
  • Lu D; Department of Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230022, People's Republic of China.
  • Zhou CZ; Department of Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230022, People's Republic of China.
  • Cheng DL; Department of Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230022, People's Republic of China.
  • Gao ZG; Infection Hospital, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230000, People's Republic of China.
  • Shi CS; Infection Hospital, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230000, People's Republic of China.
  • Su MX; Infection Hospital, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230000, People's Republic of China.
Drug Des Devel Ther ; 16: 3421-3429, 2022.
Article em En | MEDLINE | ID: mdl-36203820
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quimioembolização Terapêutica / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Drug Des Devel Ther Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quimioembolização Terapêutica / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Drug Des Devel Ther Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2022 Tipo de documento: Article